These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18669457)

  • 1. Phase II stopping rules that employ response rates and early progression.
    Goffin JR; Tu D
    J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.
    Goffin JR; Pond GR
    BMC Med Res Methodol; 2011 Dec; 11():164. PubMed ID: 22151297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
    Bradbury P; Seymour L
    Cancer J; 2009; 15(5):354-60. PubMed ID: 19826353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
    Kocherginsky M; Cohen EE; Karrison T
    J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinomial phase II cancer trials incorporating response and early progression.
    Zee B; Melnychuk D; Dancey J; Eisenhauer E
    J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stopping designs based on progression-free survival at an early time point in the initial cohort.
    Litwin S; Wong YN; Hudes G
    Stat Med; 2007 Oct; 26(24):4400-15. PubMed ID: 17345568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
    Sposto R; Gaynon PS
    Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One- and two-stage designs for stratified phase II clinical trials.
    London WB; Chang MN
    Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One- and two-stage designs for phase II window studies.
    Chang MN; Devidas M; Anderson J
    Stat Med; 2007 Jun; 26(13):2604-14. PubMed ID: 17211853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.
    Goffin JR; Pond GR; Tu D
    BMC Med Res Methodol; 2011 Jun; 11():95. PubMed ID: 21693051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some ethical issues in phase II trials in acute leukemia.
    Thall PF; Estey EH
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):943-8. PubMed ID: 16555436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.